Biocon Takes Its Oncology Biosimilars To 30 Countries In Africa And Asia
Enables Access To Trastuzumab And Pegfilgrastim Through Cancer Access Partnership
Indian company Biocon is aiming to “deliver substantial savings to healthcare systems” by enhancing access to and availability of oncology biosimilars in 25 countries in Africa and five countries in Asia, covered under the Cancer Access Partnership, led by the Clinton Health Access Initiative.
You may also be interested in...
Biocon is set to bolster its planned expansion into the MENA region through a partnership with Saudi firm Tabuk Pharmaceuticals, which will commercialize select Biocon generics in the Middle East.
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.